Home › Trials › NCT06158841

Comparing Etentamig to Standard Therapies for Relapsed Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Phase 3 Interventional AbbVie · NCT06158841

This study is testing a new drug called etentamig to see if it works better than standard treatments for adults with relapsed multiple myeloma.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment380 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Locations166 sites (Birmingham, Alabama and 165 other locations)
Trial IDNCT06158841 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of etentamig, an investigational drug, as a monotherapy in adults with relapsed or refractory multiple myeloma (MM) compared to standard available therapies. Participants are divided into two arms: one receiving etentamig and the other receiving a standard therapy chosen by the investigator. The study aims to assess changes in disease symptoms and overall effectiveness of etentamig in this patient population. Eligible participants must have measurable disease and a history of multiple prior treatments.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with relapsed or refractory multiple myeloma who have undergone at least two prior lines of therapy.

Not a fit: Patients who have not received prior treatment for multiple myeloma or those with ECOG performance status greater than 2 may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with relapsed or refractory multiple myeloma.

How similar studies have performed: Other studies have shown promise with similar investigational therapies for multiple myeloma, indicating potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance of \<= 2.
* Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
* Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:

  * Serum M-protein \>= 0.5 g/dL (\>= 5 g/L).
  * Urine M-protein \>= 200 mg/24 hours.
  * In participants without measurable serum or urine M protein, serum free light chain (FLC) \>= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio.
* Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).
* Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.

Exclusion Criteria:

* Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.
* Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study.
* Central nervous system involvement of MM.
* Has received B-cell maturation antigen (BCMA)-targeted therapy.

Where this trial is running

Birmingham, Alabama and 165 other locations

+116 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaCervinoEtentamigCarfilzomibPomalidomideElotuzumabSelinexorBortezomib
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.